找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Case-Based Gynecological Oncology; Kavita Singh,Bindiya Gupta Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive l

[復(fù)制鏈接]
樓主: 磨損
21#
發(fā)表于 2025-3-25 06:05:53 | 只看該作者
Epithelial Ovarian Cancer: High Grade SerousEpithelial ovarian cancer mainly presents in advanced stage. In recent years, treatment has been revolutionized by changes in surgical and medical management, introduction of targeted therapies and biomarker directed therapies. This change in the treatment paradigm has had substantially improved survival statistics.
22#
發(fā)表于 2025-3-25 10:39:01 | 只看該作者
Recurrent Ovarian CancerRecurrent ovarian cancer may be sensitive to platinum or platinum resistant. Management includes a combination of chemotherapy and targeted therapy. Secondary debulking surgery can be done in select cases where it is possible to achieve complete cytoreduction..This chapter will discuss clinical scenarios of recurrent ovarian cancer.
23#
發(fā)表于 2025-3-25 14:05:11 | 只看該作者
24#
發(fā)表于 2025-3-25 16:56:49 | 只看該作者
25#
發(fā)表于 2025-3-25 20:14:28 | 只看該作者
26#
發(fā)表于 2025-3-26 02:03:09 | 只看該作者
27#
發(fā)表于 2025-3-26 05:21:12 | 只看該作者
28#
發(fā)表于 2025-3-26 11:27:07 | 只看該作者
Metastatic Ovarian Canceristochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or cytoreductive surgery may be useful.
29#
發(fā)表于 2025-3-26 13:51:58 | 只看該作者
Borderline Ovarian Tumours: Early and Advance Stage: Serous, Mucinous, Micro Invasive Cancer, Invasi mild nuclear atypia without destructive stromal invasion. These account for 10–15% of all epithelial tumours. The most common subtypes are serous and mucinous tumours. Surgery is the mainstay of management and these are associated with better prognosis than invasive carcinomas.
30#
發(fā)表于 2025-3-26 19:31:56 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 20:54
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
黄大仙区| 和顺县| 临汾市| 沙湾县| 南和县| 湘潭市| 边坝县| 潞西市| 东乡县| 临沭县| 张掖市| 泰安市| 金秀| 饶河县| 成都市| 土默特左旗| 深水埗区| 新安县| 林周县| 潜山县| 延安市| 大化| 双鸭山市| 邹平县| 日土县| 平遥县| 荃湾区| 隆尧县| 法库县| 肇东市| 宝兴县| 深水埗区| 乐昌市| 襄垣县| 定兴县| 鄂托克前旗| 益阳市| 北京市| 峨山| 中卫市| 裕民县|